OptiBiotix Health Plc (LON:OPTI) a Life Sciences business developing compounds to tackle obesity, high cholesterol and diabetes, CEO Stephen O’Hara talks through the 2016 Investor Presentation. Due to popular demand, the
Stephen OHara, OptiBiotix Health Plc CEO said: ‘This report in the Express is another article highlighting concerns from the side affects from statins. This has created interest from healthcare providers
OptiBiotix Health plc (AIM: OPTI), a Life Sciences business developing compounds to tackle obesity, high cholesterol and diabetes, has told DirectorsTalk today about a change of venue for the presentation
OptiBiotix Health Plc (LON:OPTI) were the subject of an article written by G A Chester on the fool.co.uk website yesterday in which it says its growth will be largely determined
OptiBiotix Health plc (AIM: OPTI), a Life Sciences business developing compounds to tackle obesity, high cholesterol and diabetes, has told DirectorsTalk it will be holding a presentation for investors on
OptiBiotix Health plc (AIM: OPTI), a life sciences business developing products to tackle obesity, high cholesterol and diabetes, has told DirectorsTalk that it has entered into a commercial agreement with
According to an article in the Daily Mail, Statins which were designed to help protect people from heart failure could actually increase the risk of having a heart attack say
Its been a good year for investors in OptiBiotix Health plc (LON:OPTI) with an increase in the share price from 17p to 80p over the last 12 months (370% increase),
OptiBioTix Health’s Stephen O’Hara discusses the further fund raise of £2.2 million, what these funds will be used for and the opportunities in skin health in this exclusive interview with DirectorsTalk
OptiBiotix Health Plc (LON:OPTI) CEO Stephen O’Hara chats with DirectorsTalk about the further fund raise and how the money will be used. Stephen highlights some exciting opportunities in the healthcare
© 2025 – DirectorsTalk. All rights reserved. Reproduction in whole or in part, in any form or medium without express written permission is prohibited.
